Deeptech Digest | News about deeptech

CaseBioscience has launched CaseCryo CTG DMSO, a next-generation cryopreservation solution developed to support clinical cell therapy development, at Advanced...

Predicting cancer evolution

Jim Cornall - February 9, 2026

Predicting tumour progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and...

Base to Base biotech podcast 45: Chronic pain, urology, Affibody molecules and radioligand therapy

Jim Cornall - February 6, 2026

This week, we chat with Affibody CEO David Bejker, and Martin Gleave, founder and chief medical officer at Sustained...

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall - February 5, 2026

Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Breakthru Medicine emerges from stealth to develop cancer drugs

Jim Cornall - February 5, 2026

Breakthru Medicine has emerges from stealth with the close of a $60m Series A financing round following a prior...

FDA Rare Pediatric Disease designation for mucopolysaccharidosis Type II treatment

Jim Cornall - February 5, 2026

Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, has announced that the U.S. Food and...

CIRM approves $100m plan to accelerate genetic therapies for patients with rare diseases

Jim Cornall - February 4, 2026

The California Institute for Regenerative Medicine (CIRM) has approved a new funding programme to accelerate therapies for rare diseases,...

Researchers develop more reliable platform to test antibody medicines

Jim Cornall - February 4, 2026

An international research consortium, led by scientists at VIB and UGent in Belgium, has developed a new platform that...

Positive topline results from acne study

Jim Cornall - February 4, 2026

Ascletis Pharma Inc. has announced positive topline results from its phase III open-label study evaluating denifanstat (ASC40), a first-in-class,...

Sarbecovirus vaccine trial starts

Jim Cornall - February 3, 2026

SK bioscience has announced the initiation of a global phase 1/2 clinical trial in Australia for GBP511, a vaccine...

Vetter Pharma to build new manufacturing site in Germany

Jim Cornall - February 3, 2026

German CDMO Vetter has confirmed its plans to build a production facility in the Saarland region of southwest Germany. Construction...

New dementia treatment strategy proposed

Jim Cornall - February 3, 2026

Conventional treatments of Alzheimer’s disease, one of the most common forms of dementia, have been largely focused on targeting...

FDA IND clearance for Trace Biosciences’ nerve-specific imaging agent

Jim Cornall - February 2, 2026

Trace Biosciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug...

Lilly injectable medicine and device manufacturing facility to be built in Pennsylvania

Jim Cornall - February 2, 2026

Eli Lilly and Company has announced plans to invest more than $3.5bn in a new manufacturing facility in the...

A broken DNA repair tool accelerates aging

Jim Cornall - February 2, 2026

Although DNA is tightly packed and protected within the cell nucleus, it is constantly threatened by damage from normal...

Base to Base biotech podcast 44: Treating breast cancer and how a CDMO and immuno-oncology company collaborate

Jim Cornall - January 30, 2026

This week, we chat with Pan Cancer T CEO Dr. Rachel Abbott, about – among other things – triple-negative...

Two-faced nanoparticles help antibiotics treat resistant bacteria

Jim Cornall - January 29, 2026

In the global battle against antimicrobial resistance (AMR), an international research team has unveiled what it says is a...

Resolve M Therapeutics exits from stealth

Jim Cornall - January 29, 2026

Resolve M Therapeutics, Inc. has announced its exit from stealth. Resolve M was created through a strategic collaboration between...

New cancer treatment options through expanding ADC payload spectrum

Jim Cornall - January 29, 2026

Tubulis has published preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The paper, Expanding the payload...

Why tumours become aggressive and genetically unstable

Jim Cornall - January 28, 2026

A new study shows that cancer damages its own DNA by pushing key genes to work too hard. Cancer cells...

DIA launches platform to boost drug development

Jim Cornall - January 28, 2026

The Drug Information Association (DIA) has launched DIA ASCENT, a new global platform designed to support early-stage biotechnology drug...